Quantcast

Latest Biogen Idec Stories

2014-03-24 08:28:01

The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years CAMBRIDGE, MA, March 24, 2014 /CNW/ - Biogen Idec (NASDAQ: BIIB) has announced that Health Canada approved ALPROLIX((TM) )[Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. ALPROLIX is the first approved long-acting hemophilia B therapy and...

2014-03-22 12:21:28

DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include...

2014-03-14 20:21:06

NEW YORK, March 14, 2014 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, March 21: -- S&P 500 constituent Biogen Idec Inc. (NASD:BIIB) will replace S&P 500 constituent American Electric Power Company Inc. (NYSE:AEP) in the S&P 100. Biogen Idec has a market capitalization above $80 billion and is more...

2014-03-12 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 12, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2014-02-25 23:31:44

Ruth E. Hager is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession. Garden City, NY (PRWEB) February 25, 2014 NAPW honors Ruth E. Hager as a 2013/2014 Professional Woman of the Year for leadership with this prestigious distinction. As the largest, most-recognized organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women is a powerfully vibrant...

2014-02-21 16:23:09

On track to initiate Phase 3 study in infants with SMA in the middle of this year CARLSBAD, Calif., Feb. 21, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). To date, all four infants in the 6 mg cohort have been in the study for over six months and are now approximately nine and a half to 16 months in age with an average age...

2014-02-13 08:30:17

--Isis will receive $9.3 million in milestone payments -- CARLSBAD, Calif., Feb. 13, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN(Rx) in children with spinal muscular atrophy (SMA). Isis also announced today that the first child was dosed in an open-label extension study, which is being offered to those children with SMA who have completed dosing in...

2014-02-11 16:25:42

Significant Clinical and Preclinical Data Presentations in Fourth Quarter of 2013 Highlight Transformational Year RICHMOND, Calif., Feb. 11, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2013 financial results and accomplishments. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) For the fourth quarter ended December 31, 2013, Sangamo reported a consolidated net loss of $8.1 million, or $0.13 per share, compared to a net...

2014-02-04 08:34:43

CAMBRIDGE, Mass., Feb. 4, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an...

2014-01-14 12:26:25

CHICAGO, Jan. 14, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sangamo BioSciences, Inc. (Nasdaq:SGMO-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Shire (Nasdaq:SHPG-Free Report), Actelion (OTC:ALIOF-Free Report) and eHealth, Inc. (Nasdaq:EHTH-Free Report)....


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related